05 December 2019

NICE, Level 1, City Tower, Piccadilly Plaza, Manchester, M1 4BT

Final agenda 

The meeting will start promptly at 10:00 and is expected to finish at approximately 17:00

Please note that this agenda is subject to change before the meeting.

  1. Welcome and introduction to format of meeting – Part 1 only (open session)
  2. Apologies – Part 1 only (open session)
  3. Any other business – Part 1 only (open session)
  4. Minutes from the last committee meeting held on Wednesday 6 November 2019 – Part 1 only (open session)
  5. Appraisal of trifluridine–tipiracil for treating metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID1507]
           5.1. Declarations of interest – Part 1 only (open session)
           5.2. Introduction by the Chair, Professor Peter Selby– Part 1 only (open session)
           5.3. Presentation by the lead team: Alex Cale (clinical), Michael Chambers (cost), Stella O’Brien (lay)  Part 1 and Part 2  (open and closed session)
           5.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  6. Appraisal of Pembrolizumab for treating recurrent or metastatic squamous cell head and neck cancer [ID1140]
           6.1. Declarations of interest – Part 1 only (open session)
           6.2. Introduction by the Vice Chair, Dr Lindsay Smith– Part 1 only (open session)
           6.3. Presentation by the lead team: Paula Ghaneh (clinical), Rob Hodgson (cost), Rebecca Harmston (lay) Part 1 and Part 2  (open and closed session)
           6.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  7. Appraisal of Gilteritinib for treating relapsed or refractory acute myeloid leukaemia [ID1484]
          7.1. Declarations of interest – Part 1 only (open session)
          7.2. Introduction by the Chair, Professor Stephen O'Brien– Part 1 only (open session)
          7.3. Presentation by the lead team: Rob Forsyth (clinical), Natalie Hallas (cost), Stella O’Brien (lay) Part 1 and Part 2  (open and closed session)
          7.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)
  8. Appraisal of Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID1504]
    • 8.1. Declarations of interest – Part 1 only (open session)
    • 8.2. Introduction by the Chair, Professor Stephen O'Brien– Part 1 only (open session)
    • 8.3. Presentation by the Chair, Professor Stephen O’Brien– Part 1 and Part 2  (open and closed session)
    • 8.4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) – Part 2 only (closed session)

To print an agenda, please right click and select 'Print' from the menu.

Date, time and venue of next meeting

The next meeting will take place on Wednesday 22 January 2020 at 10:00, at NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT.

Please note all timings are approximate.

How to register

  • Click on the register link below and complete the registration form, selecting the topics you would like to attend.
  • You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.
  • Registration will close on Thursday 21 November 2019Please note that it may not be possible to accept late requests. 
  • Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Sandra Robinson.
  • Registrants wishing to conduct a research study on committee meetings and/or NICE processes will require prior permission. Contact the NICE Enquiry Handling team at nice@nice.org.uk.
  • Further information about conducting research is also available in our common questions and answers about meetings in public document.

 

Registration period: 07 to 21 November 2019
Registration is closed.